Knowledge is power. When you know the truth, regardless of how troubling it might be, you can do all within your power to make a grave situation better. Oncotarget is that one medical journal that gives the world the power of knowledge as far as health is concerned. Created in 2010, Oncotarget has had a tremendous impact helping transform the health sector in more ways than one.Oncotarget, in the seven years’ that it has been in existence has mainly produced vast volumes of scientific literature concentrating on fields like endocrinology, metabolism, pathology, chromosome, autophagy, cell diseases, neuroscience, stem cell, age related diseases, aging, physiology, immunology, and Oncotarget.
From the very beginning, Oncotarget has experienced a huge presence, due to outstanding content produced by its two editors, Mikhail Blagosklonny and Andrei V. Gudkov. Taking the role of social media in modern society, Oncotarget has leveraged the power of the people through social accounts like Twitter, Facebook, YouTube, and Google+.Seven years after inception, Oncotarget remains a vital resource to the pursuit of finding a cure for cancer. As a huge contributor of Oncotarget knowledge, Mikhail Blagosklonny has gone above and beyond to try and find a connection between cancer and aging. Mikhail has been overly concerned as to why many old people have cancer and related illnesses. Blagosklonny believes that if he finds that link between the above two factors, he will be a step closer to finding a cure to the cancer menace.
Today, Oncotarget publishes papers on a weekly basis, meaning that research data gets updated regularly. To this end, Oncotarget has become a major reference point for scholars across the globe with more than sixty percent of Oncotarget readers citing sources from the weekly journal. As per the American National Statistics, Oncotarget ranks at number sixty-six, an impressive value for a journal of its age.Thanks to Oncotarget, the future looks bright as far as medical science is concerned. For seven years, Oncotarget has indirectly stimulated a health research revolution that has given scientists across the globe a platform to provide patients with medical breakthroughs.
Clay Siegall is one of the nation’s foremost pharmaceutical researchers. Specializing in the development of antibody drug conjugates, a type of drug that uses synthetic human antibodies to deliver a highly lethal cytotoxin directly to the site of malignant tumors, Dr. Siegall is responsible for the development of some of the most cutting-edge cancer treatments seen since the 1950s. After a career of more than 30 years of developing some of the most innovative cancer treatments in the world, Dr. Siegall now leads his own firm, Seattle Genetics, which is credited with the first ever FDA-approved antibody drug conjugate, ADCetris, for the treatment of refractory non-Hodgkin’s lymphoma.
Dr. Clay Siegall first became interested in cancer research while still attending college. A family member became ill with the disease while Dr. Siegall was still in undergraduate school. At one point, the family member developed severe anemia, nearly leading to their death. This is what made Dr. Siegall realize that there must be a better way to treat cancer than to use drugs that oftentimes have death as a side effect. The brutality and crudeness of standard chemotherapeutics regimens left Dr. Siegall certain that there must be another way to treat this terrible disease.
After receiving a PhD in genetics from George Washington University, Dr. Siegall was hired on by the National Cancer Institute, one of the most prominent cancer research organizations in the world. He worked there for four years, working on an exciting new class of drugs known as targeted cancer therapies. After spending time learning the trade at the National Cancer Institute, Dr. Siegall was hired by Bristol-Myers Squibb, one of the leading private pharmaceutical companies in the world.
While at Bristol-Myers Squibb, Dr. Siegall rose to the rank of senior researcher, leading a team of his own scientists that he exclusively dedicated to the research and development of new types of targeted cancer therapy. It was during this time that Dr. Siegall became aware of the possibility of using human antibodies to deliver a highly lethal cytotoxin directly to the site of a malignant tumor. He eventually synthesized prototypical drugs of this type, calling them antibody drug conjugates.
Dr. Siegall immediately realized the enormous commercial potential for this new line of drugs. He eventually left Bristol-Myers Squibb and started his own biotech firm, Seattle Genetics. Seattle Genetics would be exclusively dedicated to the research and development of antibody drug conjugates, focusing on cancer types that had not seen significant mortality improvements in decades.
Today, Seattle Genetics is the only company to have received FDA approval for an antibody drug conjugate. It continues saving thousands of lives each year.